Leerink Partners Upgrades enGene to Outperform
Leerink Partners upgraded enGene to Outperform from Market Perform with a $5 price target.
Stocks · News reference
Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Market Perform.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Leerink Partners upgraded enGene to Outperform from Market Perform with a $5 price target.
Analysts upgraded AMD, Reliance, enGene, Mid Penn Bancorp and Republic Services, raising price targets for RS and MPB.
enGene Therapeutics announced updated clinical data for its lead candidate, detalimogene voraplasmid, and the appointment of a new Chief Medical Officer and Chief Legal and Administrative Officer.
enGene Therapeutics Inc. announced that its management team will participate in two upcoming investor conferences in November 2026.
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of $(0.57) per share from